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Eﬀ ect of HIV infection on pregnancy-related mortality in 
sub-Saharan Africa: secondary analyses of pooled community-
based data from the network for Analysing Longitudinal 
Population-based HIV/AIDS data on Africa (ALPHA)
Basia Zaba, Clara Calvert, Milly Marston, Raphael Isingo, Jessica Nakiyingi-Miiro, Tom Lutalo, Amelia Crampin, Laura Robertson, Kobus Herbst, 
Marie-Louise Newell, Jim Todd, Peter Byass, Ties Boerma, Carine Ronsmans 
Summary
Background Model-based estimates of the global proportions of maternal deaths that are in HIV-infected women 
range from 7% to 21%, and the eﬀ ects of HIV on the risk of maternal death is highly uncertain. We used longitudinal 
data from the Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA) network to estimate the 
excess mortality associated with HIV during pregnancy and the post-partum period in sub-Saharan Africa.
Methods The ALPHA network pooled data gathered between June, 1989 and April, 2012 in six community-based 
studies in eastern and southern Africa with HIV serological surveillance and verbal-autopsy reporting. Deaths 
occurring during pregnancy and up to 42 days post partum were deﬁ ned as pregnancy related. Pregnant or post-
partum person-years were calculated for HIV-infected and HIV-uninfected women, and HIV-infected to HIV-
uninfected mortality rate ratios and HIV-attributable rates were compared between pregnant or post-partum women 
and women who were not pregnant or post partum. 
Findings 138 074 women aged 15–49 years contributed 636 213 person-years of observation. 49 568 women had 
86 963 pregnancies. 6760 of these women died, 235 of them during pregnancy or the post-partum period. Mean 
prevalence of HIV infection across all person-years in the pooled data was 17·2% (95% CI 17·0–17·3), but 
60 of 118 (50·8%) of the women of known HIV status who died during pregnancy or post partum were HIV infected. 
The mortality rate ratio of HIV-infected to HIV-uninfected women was 20·5 (18·9–22·4) in women who were not 
pregnant or post partum and 8·2 (5·7–11·8) in pregnant or post-partum women. Excess mortality attributable to HIV 
was 51·8 (47·8–53·8) per 1000 person-years in women who were not pregnant or post partum and 11·8 (8·4–15·3) 
per 1000 person-years in pregnant or post-partum women. 
Interpretation HIV-infected pregnant or post-partum women had around eight times higher mortality than did their 
HIV-uninfected counterparts. On the basis of this estimate, we predict that roughly 24% of deaths in pregnant or 
post-partum women are attributable to HIV in sub-Saharan Africa, suggesting that safe motherhood programmes 
should pay special attention to the needs of HIV-infected pregnant or post-partum women.
Funding Wellcome Trust, Health Metrics Network (WHO).
Introduction
Indicators for measuring progress towards the Millen-
nium Development Goals include maternal mortality 
(the ﬁ fth Millennium Development Goal) and HIV/
AIDS-associated mortality (the sixth Millennium 
Develop ment Goal). In sub-Saharan Africa, the high 
prevalence of HIV infection in pregnant women makes 
the interaction between HIV and maternal mortality an 
important public health issue. In the 2011 follow-up of 
the UN General Assembly, a speciﬁ c goal on HIV and 
maternal mortality was set—ie, to halve HIV mortality 
in pregnant or post-partum women by 2015.1 The 
substantial increase in adult mortality because of HIV, 
which has been noted in many studies in sub-Saharan 
Africa,2,3 might have an adverse eﬀ ect on pregnancy-
related mortality even if the link between HIV and 
maternal death is not causal, and aﬀ ects the reliability 
of assessments of progress towards the ﬁ fth Millennium 
Development Goal.
Although recent estimates have suggested that maternal 
mortality is decreasing worldwide, worrying increases 
have been noted in some countries in sub-Saharan Africa. 
WHO estimates that the maternal mortality ratio increased 
by more than 40% in all countries in southern Africa 
between 1990 and 2005.4,5 In Zimbabwe, the maternal 
mortality ratio increased by a factor of 2·5 between 1985 
and 1994, and in Malawi it increased by a factor of 1·8 
between 1995 and 1999.6 Reasons for these increases are 
poorly understood. The increasing prevalence of HIV 
infection is thought to be the main driver,4,5 but empirical 
evidence supporting this assertion is weak. 
The contribution of HIV to maternal mortality can be 
measured by calculating the proportion of maternal 
deaths attributed to HIV. A systematic review7 of 
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population-based studies published between 1997 and 
2002 examining the cause distribution of maternal deaths 
showed that 6·2% of maternal deaths in Africa can be 
attributed to HIV/AIDS (based on eight Africa-based 
studies). Most studies that have been published so far are 
facility based. Some hospital-based studies8–11 in areas 
where the prevalence of HIV infection is high have shown 
that HIV/AIDS is one of the leading causes of pregnancy-
related deaths. In a tertiary hospital in South Africa, more 
than 40% of maternal deaths were loosely attributed to 
HIV/AIDS,9 and, in a 2012 analysis12 of all institutional 
maternal deaths in South Africa in 2008–10, 70% were in 
HIV-infected women. Because of the scarcity of empirical 
data for the interaction between HIV and maternal 
mortality, most estimates of the contribution of HIV to 
maternal mortality rely on mathematical models with 
inbuilt assumptions about how HIV interacts with 
pregnancy. A model developed by the Institute of Health 
Metrics and Evaluation assumed that all deaths in HIV-
infected pregnant or post-partum women should be 
classiﬁ ed as maternal; as a result, roughly 20·5% of 
maternal deaths in 2011 were attributed to HIV globally.5 
Another model, which was produced by the UN Maternal 
Mortality Estimation Inter-agency Group, assumed that 
only 50% of deaths in HIV-infected pregnant or post-
partum women were maternal; 6·5% of the global 
maternal deaths in 2010 were estimated to be attributable 
to HIV/AIDS on the basis of this model.4 
An alternative measure of the contribution of HIV to 
mortality during pregnancy is the excess mortality 
associated with HIV in pregnant or post-partum women. 
On the basis of a systematic review13 of 23 studies, 17 of 
which were done in sub-Saharan Africa, HIV-infected 
pregnant or post-partum women were estimated to have 
nearly eight times the risk of death that non-HIV-infected 
women had. The authors of the review, which was 
focused on pregnancy-related mortality rather than 
maternal mortality, used this risk ratio to predict that 
roughly 25% of pregnancy-related deaths in sub-Saharan 
Africa were attributable to HIV. 
The paucity of empirical data for the eﬀ ect of HIV on 
mortality during pregnancy is largely the result of 
diﬃ  culties with methods. In most community-based 
studies, the HIV status of women and girls who die is 
unknown, and very few maternal deaths are encountered. 
We use longitudinal data from the network for Analysing 
Longitudinal Population-based HIV/AIDS data on Africa 
(ALPHA), which links ten HIV community-based cohort 
studies14 from eastern and southern Africa (six of which 
have the necessary data), to calculate the excess mortality 
associated with HIV during pregnancy and the post-
partum period. 
Methods
Study design
We used data from six independently established studies 
in Karonga, Kisesa, Manicaland, Masaka, Rakai, and 
uMkhanyakude in our analysis. Fieldwork methods for 
each study have been described in detail elsewhere.15–20 
Brieﬂ y, the studies recorded demographic data—ie, dates 
of births (of both mothers and infants), deaths, and, 
except for Karonga and Rakai, dates of pregnancy reports. 
Each study also provided dates and results of HIV tests 
for their surveillance populations. In Karonga, Kisesa, 
Rakai, and uMkhanyakude, the demo graphic and HIV 
surveys were done separately, and data were linked via 
unique personal identiﬁ ers. In Manicaland and Masaka, 
household censuses were administered to record 
demographic events and list eligible participants for HIV 
testing immediately before serological surveillance. 
HIV test protocols diﬀ er between studies and have 
changed with time, and details of test kits used at each site 
since 1990 have been published.21–26 HIV testing was done 
in the home, except in Kisesa, where serological sur-
veillance was done in specially constructed temporary 
village clinics, to which people were transported by project 
vehicles from their homes. Before 2003, all studies 
(excluding Karonga) followed a research test protocol of 
informed consent without disclosure (in uMkhanyakude, 
participants received detailed verbal and written pretest 
information), but as antiretroviral therapy (ART) became 
available, testing protocols that oﬀ er, but do not insist 
upon, full pretest and post-test counselling were gradually 
adopted. Karonga had always oﬀ ered full pretest and post-
test counselling. 
Procedures
A common format and coding system were agreed with 
the six African study sites for all data variables used in 
the analyses. After a series of analysis workshops, each 
study contributed a dataset meeting the agreed 
speciﬁ cation, and the data were pooled by analysts at the 
London School of Hygiene & Tropical Medicine 
(London, UK). Data management programs were 
developed in Stata (version 12) to clean the pooled 
dataset, so that all data met the same validity and 
consistency criteria statistical analysis. The data 
cleaning programs and the subsequent statistical 
analyses programs were made available to the study 
sites for further use with their own data. Analyses 
presented in this Article relate to all deaths occurring in 
pregnant or post-partum women (up to 42 days’ post 
partum). We did not exclude causes that are incidental 
to pregnancy, and thus we use the term pregnancy-
related mortality rather than maternal mortality to 
describe our ﬁ ndings. 
Verbal-autopsy interviews are structured interviews with 
persons who cared for or were close to the deceased 
during the ﬁ nal illness, and can report signs and 
symptoms that they noted during this period.27 Interviews 
were triggered by reports of deaths collected during 
demographic surveillance at all sites except Manicaland 
and Masaka, where community-based infor mants were 
used. At Masaka, the deaths for which verbal-autopsy 
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interviews were done occurred between March, 1990, and 
November, 1992, or between January, 2006, and November, 
2008; data were gathered continuously at all other sites. 
Instruments for verbal autopsies were developed largely 
independently by each study, with convergence to 
compatibility with international standards by 2011.28,29 We 
used only two sets of responses in this analysis—those to 
questions about whether the woman was pregnant or post 
partum when she died and whether she had ever tested 
positive for HIV infection.
In accordance with the tenth revision of the Inter-
national Classiﬁ cation of Diseases,30 we classiﬁ ed death 
as pregnancy related if it occurred while the woman was 
pregnant or post partum, irrespective of the cause of 
death. Pregnancy or birth reports that identiﬁ ed a death 
as pregnancy related were obtained either from demo-
graphic surveillance or from verbal autopsies. 
Statistical analysis
Person-time at risk of a pregnancy-related death was 
calculated. For births recorded by demographic 
surveillance, 280 days of pregnancy (unless curtailed by 
the woman arriving in the study area after the start of 
her pregnancy) and 42 days’ post-partum exposure 
(unless curtailed by the woman’s death or departure 
from the study area) were assumed for calculations of 
person-time at risk of pregnancy-related death. When 
pregnancy was recorded (either by demographic 
surveillance or verbal autopsy) but no birth report 
obtained (because the woman died or left the study area 
before delivery), we assumed that the pregnancy report 
was made on day 185 of the pregnancy—ie, halfway 
between day 90 and day 280—on the grounds that 
pregnancies would be unlikely to be recognised and 
reported before the ﬁ rst trimester. 
In our analysis, women have a risk of dying or giving 
birth as soon as they turn 15 years old and have been 
listed as members of a study household during demo-
graphic surveillance. The risk period ends when they are 
aged 50 years or older or leave the study area through 
death or migration. 
Person-time is classiﬁ ed as HIV uninfected from the 
ﬁ rst HIV-negative test date to a predetermined period 
after the last HIV-negative test. For women who sub-
sequently test positive for HIV infection, the remaining 
HIV-uninfected period is half the interval between the 
last negative test and the ﬁ rst positive test. For women 
who do not test positive after their last HIV-negative test, 
the remaining HIV-uninfected period was deﬁ ned as 
5 years for Karonga, Kisesa, Masaka, and Rakai, 3 years 
for Manicaland, and 1·5 years for uMmkhanyukude. 
These periods roughly correspond to the time that it 
would take for 5% of HIV-uninfected women at the 
diﬀ erent study sites to seroconvert.
Person-time after the ﬁ rst HIV-positive test was 
classiﬁ ed as HIV infected, as was half the person-time in a 
seroconversion period. Verbal autopsies might identify 
HIV-infected women who had not tested positive in a 
serosurvey, such as women who were tested before 
moving to the study area or tested outside the research 
setting (eg, at an antenatal clinic) and subsequently did 
not take part in research tests. To avoid counting these 
deaths without allocation of an appropriate amount of 
person-time at risk, we assumed that women who were 
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Location Karonga Kisesa Manicaland Masaka Rakai uMkhanyakude
Dates for which HIV data are 
available
2005–12 1994–2011 1994–2008 1989–2011 1994–2009 2003–11
Prevalence of HIV infection* 
at start date (%)
12% 5% 24% 7% 16% 22%
Prevalence of HIV infection* 
at end date (%)
8% 6% 14% 9% 11% 29%
Population at start date (n) 31 000 20 000 15 000 8000 30 000 93 000
Population at end date (n) 35 000 34 000 37 000 19 000 40 000 96 000
Frequency of data collection Continuous 
(through key 
informants)
Every 6 months Every 2–3 years Every year Every 14–16 months Every 6 months
Frequency of HIV data 
collection
Variable (< every 
3 years)
Every 3 years Every 2–3 years Every year Every 14–16 months Every year
Collection periods for 
verbal-autopsy data
2003–12 1994–2011 1994–2008 1990–92, 2006–08 1996–2009 2003–11
Period of roll-out of ART 2005–06 2005–08 2007–09 2004–05 2004–06 2004–06
Populations are rough estimates; numbers are rounded for ease of comparison. ART=antiretroviral therapy. *In people aged 15 years or older. 
Table 1: Characteristics of Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA) study sites contributing data for HIV and 
maternal mortality
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established to be HIV infected on the basis of verbal 
autopsies had been infected for 5 years—ie, half the 
median postinfection survival time in the pooled dataset.17
We classiﬁ ed person-time for women who were never 
tested and person-time lived outside that classiﬁ ed as 
HIV infected or HIV uninfected as HIV status unknown. 
We divided exposure years into calendar time before ART 
was available, during ART rollout, and after widespread 
ART availability in health facilities serving each study. 
The period prevalence of HIV infection was calculated 
by dividing the HIV-infected person-years by the sum 
of the years of known HIV status. We estimated the 
general fertility rate as the total number of births 
divided by the total number of person-years to women 
of reproduc tive age. 
We calculated mortality rates per 1000 person-years by 
pregnancy and HIV status, and used the age distribution 
of all women as a standard to calculate age-standardised 
mortality. The rate ratio was calculated by dividing the 
mortality rate in HIV-infected women by that in HIV-
uninfected women for pregnant or post-partum women 
and for those who were not pregnant or post partum. For 
the pooled dataset, we used Mantel-Haenzhel estimates 
to calculate an age-adjusted rate ratio, but could not 
calculate age-adjusted rate ratios for each site because of 
small numbers. 
To quantify the excess risk of mortality in HIV-infected 
women, the attributable rate was calculated as the 
mortal ity rate in HIV-infected women minus that in 
HIV-uninfected women. We divided the attributable 
rate by the mortality rate in HIV-infected women to 
calculate the attributable rate percentage of deaths due 
to HIV infection. To assess the eﬀ ect of HIV on mortality 
at the population level, we calculated the population-
attributable rate—ie, the mortality rate in all women 
minus that in HIV-uninfected women. We then divided 
the population-attributable rate by the mortality rate in 
all women to give the population-attributable frac-
tion (PAF). To predict PAFs in pregnant women in 
populations with known prevalences of HIV infection 
on the basis of noted rate ratios of mortality of HIV-
infected to HIV-uninfected pregnant or post-partum 
women in the pooled ALPHA dataset, we used the 
standard relation:31
Results
Table 1 lists the six independently established studies 
that contributed data for our analysis. 138 074 women 
aged 15–49 years contributed 636 213 person-years of 
observation between June, 1989, and April, 2012. HIV 
status was known for 321 817 of 636 213 (50·6%) person-
years (table 2). 49 568 women had 86 963 pregnancies; 
HIV status was known during 49 740 (57·2%) of these 
pregnancies. 6760 deaths were reported in women of 
reproductive age, of which 3709 (54·9%) could be 
classiﬁ ed by HIV status (table 3). Of the 235 of these 
deaths that were in women who were pregnant or post 
partum, HIV status was known for 118 (50·2%; table 3). 
The overall mean prevalence of HIV infection during 
the data collection period in the pooled dataset was 
17·2% (95% CI 17·0–17·3). Prevalence in pregnant or 
post-partum women (11·2% [10·9–11·5]) was signiﬁ cantly 
lower than that in women who were not pregnant or post 
partum (18·0% [17·9–18·1]; p<0·0001). The appendix 
shows the prevalence of HIV infection in women of 
reproductive age by year. Mean prevalence was 7·2% 
(7·0–7·4) in Kisesa, 8·2% (7·9–8·4) in Masaka, 9·6% 
(9·2–10·0) in Karonga, 15·7% (15·5–15·9) in Rakai, 
24·5% (24·0–25·0) in Manicaland, and 35·4% 
(35·0–35·8) in uMkhanyakude. Mean preva lence in 
women who were pregnant or post partum was signiﬁ -
cantly lower than that in women who were not pregnant 
or post partum (data not shown).
The general fertility rate in the pooled dataset was 132 
(95% CI 131–133) births per thousand person-years. 
Fertility rates were signiﬁ cantly lower in HIV-infected 
women (100 [97–104]) than in HIV-uninfected women 
(172 [170–174]; p<0·0001). General fertility rates were 
lower in the southern African sites—ie, Manicaland (85·8 
[82·5–89·1]) and uMkhanyakude (98·2 [96·9–99·5])— 
than in the east African sites—ie, Karonga (190·5 
[187·1–194·0]), Kisesa (180·6 [177·9–183·4]), Masaka 
(157·9 [154·7–161·2]), and Rakai (125·1 [123·3–126·9]). 
Deaths Person-years Mortality per 1000 
person-years (95% CI)
Age-standardised 
mortality per 1000 
person-years (95% CI)
Not pregnant and more than 42 days post partum
Known HIV status 3591 282 664 12·7 (12·3–13·1) 12·8 (12·4–13·2)
HIV uninfected 652 231 804 2·8 (2·6–3·0) 2·8 (2·6–3·0)
HIV infected 2939 50 859 57·8 (55·7–59·9) 57·6 (55·5–59·6)
Unknown HIV status 2934 284 960 10·3 (9·9–10·7) 10·3 (9·9–10·7)
Total 6525 567 624 11·5 (11·2–11·8) 11·5 (11·3–11·8)
Pregnant or up to 42 days post partum
Known HIV status 118 39 153 3·0 (2·5–3·6) 3·6 (2·3–5·0)
HIV uninfected 58 34 774 1·7 (1·3–2·2) 2·4 (1·0–3·8)
HIV infected 60 4380 13·7 (10·6–17·6) 16·1 (10·3–21·9)
Unknown HIV status 117 29 436 4·0 (3·3–4·8) 5·2 (3·0–7·3)
Total 235 68 590 3·4 (3·0–3·9) 4·3 (3·1–5·5)
All women of reproductive age
Known HIV status 3709 321 817 11·5 (11·2–11·9) ··
Negative 710 266 578 2·7 (2·5–2·9) ··
Positive 2999 55 240 54·3 (52·4–56·3) ··
Unknown HIV status 3051 314 396 9·7 (9·4–10·1) ··
Total 6760 636 213 10·6 (10·4–10·9) ··
Data in the person-years column might not add exactly because of rounding.
Table 2: Mortality in pooled Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA) 
network data by pregnancy and HIV status, 1990–2012
PAF =
prevalence rate ratio – 1
1 + prevalence rate ratio – 1
( )
( )
×
×
See Online for appendix
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Mortality in HIV-uninfected women was 1·5 (95% CI 
1·1–1·9) per 1000 person-years at uMkhanyakude, which 
was lower than that at the other sites combined 
(2·9 [0·27–0·31] per 1000 person-years). 
Table 3 shows the distribution of deaths at each site 
classiﬁ ed by HIV status and whether or not women were 
pregnant or post partum. The uMkhanyakude site 
contributed 29·3% of all the deaths in women of known 
HIV status, 22·9% of the pregnancy-related deaths in 
women of known HIV status, and 34·3% of all deaths in 
HIV-infected women (table 3). 
Of the 235 pregnancy-related deaths, 40 (17·0%) were 
identiﬁ ed as pregnancy related by both verbal-autopsy 
data and demographic surveillance data, 144 (61·3%) 
were identiﬁ ed as pregnancy related on the basis of 
verbal-autopsy reports alone, and the remaining 51 
(21·7%) were identiﬁ ed through demographic surveil-
lance only. In this last group of 51, verbal autopsy was not 
done in 24 cases and did not directly identify the death as 
pregnancy related in 27 cases. The study with the lowest 
proportion of pregnancy-related deaths with verbal-
autopsy data was Masaka (23·1%). Rakai relied exclusively 
on verbal autopsies to identify pregnancy-related deaths. 
In Kisesa and Manicaland, less than 20% of the 
pregnancy-related deaths were identiﬁ ed as such via 
demographic surveillance system (data not shown).
Overall mortality in the pooled dataset was 10·6 
(95% CI 10·4–10·9) per 1000 person-years. In HIV-
infected women, overall mortality was 54·3 (52·4–56·3) 
per 1000 person-years compared with 2·7 (2·5–2·9) in 
HIV-uninfected women. It was 9·7 (9·4–10·1) per 
1000 person-years in women of unknown HIV status, 
which was lower than the mean mortality of women with 
known HIV status (11·5 [11·2–11·9] per 1000 person-
years). 49·2% of the person-years of unknown HIV 
status were contributed by the uMkhanyakude site, 
where participation rates in HIV surveillance were lower 
than at other sites (data not shown).
Table 2 shows deaths, person-years of exposure, and 
resulting mortality by pregnancy or post-partum status 
and HIV status. 60 of 118 (50·8%) pregnant or post-
partum women of known HIV status who died were 
infected with HIV (table 2). The appendix contains a 
further breakdown of these results by study site. 
During the study period, HIV-infected women had 
much higher mortality than had uninfected women. The 
crude rate ratio of mortality in HIV-infected women who 
were not pregnant or post partum to that in HIV-
uninfected women who were not pregnant or post 
partum was 20·5 (95% CI 18·9–22·4); in pregnant or 
post-partum women, the corresponding rate ratio is 8·2 
(5·7–11·8; table 4). After adjustment for age, the rate 
ratio for women who were not pregnant or post partum 
fell to 19·0 (17·3–20·8) and that for pregnant or post-
partum women increased slightly to 9·0 (6·1–13·1). 
Mortality rate ratios varied substantially across study 
sites (table 4). At all sites, the rate ratios were substantially 
higher in women who were not pregnant or post partum 
than in those who were pregnant or post partum, with 
the exception of Manicaland, where the ratios were very 
similar in the two groups (table 4). Sensitivity analyses 
showed little eﬀ ect on the crude rate ratio of varying the 
assumptions around the person-time allo cated as HIV 
infected before death for HIV infection reported in verbal 
autopsies, or HIV uninfected time after a last HIV 
negative test (appendix).
Figure 1 shows the mortality rates for women with 
known HIV status, broken down by availability of ART. 
Mortality fell substantially in HIV-infected women who 
Crude rate ratio  (95% CI) Population-attributable fraction
Pregnant or 
post partum
Not pregnant or 
post partum
Pregnant or 
post partum
Not pregnant or 
post partum
Karonga 11·7 (3·7–37·0) 38·7 (25·1–59·7) 38·0 79·3
Kisesa 4·4 (1·9–10·1) 15·2 (12·1–19·2) 14·6 51.7
Manicaland 9·5 (3·9–23·4) 8·9 (7·5–10·4) 60·8 65·7
Masaka 5·9 (1·5–22·9) 30·5 (24·5–37·9) 24·9 70·9
Rakai 13·4 (3·8–47·4) 28·7 (23·9–34·5) 55·5 82·0
uMkhanyukude 16·8 (5·1–55·9) 32·4 (24·7–42·3) 83·5 91·7
All sites 8·2 (5·7–11·8) 20·5 (18·9–22·4) 44·6 77·6
 Table 4: Crude rate ratio of mortality rates in HIV-infected and HIV-uninfected women and population-
attributable fraction for HIV, by study site
Karonga Kisesa Manicaland Masaka Rakai uMkhanyakude Total
Pregnancy-related deaths
HIV uninfected 7/42 (17%) 30/62 (48%) 7/23 (30%) 7/13 (54%) 4/20 (20%) 3/75 (4%) 58/235 (25%)
HIV infected 5/42 (12%) 7/62 (11%) 15/23 (65%) 3/13 (23%) 6/20 (30%) 24/75 (32%) 60/235 (26%)
Unknown 30/42 (71%) 25/62 (40%) 1/23 (4%) 3/13 (23%) 10/20 (50%) 48/75 (64%) 117/235 (50%)
All other deaths
HIV uninfected 25/321 (8%) 127/545 (23%) 199/806 (25%) 110/580 (19%) 135 /1468 (9%) 56/2805 (2%) 652/6525 (10%)
HIV infected 110/321 (34%) 159/545 (29%) 588/806 (73%) 305/580 (53%) 772/1468 (53%) 1005/2805 (36%) 2939/6525 (45%)
Unknown 186/321 (58%) 259/545 (48%) 19/806 (2%) 165/580 (28%) 561/1468 (38%) 1744/2805 (62%) 2934/6525 (45%)
Data are n/N (%). Because of rounding, percentages do not always total 100%. 
Table 3: Deaths in women and girls aged 15–49 years by study site, pregnancy, and HIV status
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were not pregnant or post partum; the mortality rate 
ratio comparing the post-ART period with the pre-ART 
period was 0·42 (p<0·0001). In woman who were preg-
nant or post partum, the fall was much smaller (0·70 
[p=0·205]).
In HIV-infected pregnant or post-partum women, 
the HIV-attributable rate of mortality was 11·8 per 
1000 person-years (95% CI 8·4–15·3), and the HIV-
attributable risk percentage was 87·7% (82·3–91·4). The 
corresponding HIV-attributable rate in HIV-infected 
women who were not pregnant or post partum was 
51·8 per 1000 person-years (49·8–53·8) and the HIV-
attributable risk percentage was 94·9% (94·4–95·3). In 
all pregnant or post-partum women with known HIV 
status, the population-attributable rate was 1·3 per 
1000 person-years, and the PAF was 44·6%. For women 
with known HIV status who were not pregnant or post 
partum, the population-attributable rate was 9·9 per 
1000 person-years and the PAF was 77·6%. 
Figure 2 compares, for each study, the proportion of 
pregnant or post-partum women infected with HIV at 
the time of their death, with the mean prevalence of HIV 
infection in the child-bearing popu lation during the 
study period. The relation was not linear, but prevalence 
of HIV infection in living pregnant or post-partum 
women (range 7–35) was asso ciated with that in pregnant 
or post-partum women who died (19–89). Prevalence of 
HIV infection in pregnant or post-partum women who 
died was between 2·5 and 4·5 times that in living women 
aged 15–50 years.
Discussion
In the pooled ALPHA data, HIV-infected pregnant or 
post-partum women had an eight-times higher risk of 
dying than did HIV-uninfected counterparts (panel). In 
women who were not pregnant or post partum, the risk 
in HIV-infected women was slightly more than 20 times 
that in HIV-uninfected women. Excess mortality attribu-
table to HIV was substantially lower in HIV-infected 
pregnant or post-partum women than that in HIV-
infected women who were not pregnant or post partum. 
Thus, the HIV PAF is much smaller for pregnant or 
post-partum women than for women who were not 
pregnant or post partum (78%). 
Lower excess mortality attributable to HIV in HIV-
infected pregnant or post-partum women than in HIV-
infected women who are not pregnant or post partum is 
perhaps not surprising. Although HIV has been classi ﬁ ed 
by some analysts as an indirect cause of maternal death5— 
implying that HIV disease progression is aggravated by 
pregnancy—evidence for the adverse eﬀ ect of pregnancy 
on HIV progression and mortality in HIV-infected women 
is weak.7 Excess mortality might be counter-balanced by 
the fact that fertility falls rapidly with duration of HIV 
infection34 and with age, whereas mortality increases with 
age and rises very rapidly with duration of HIV infection. 
When women are ill with AIDS or an AIDS-related 
disorder, they are unlikely to become pregnant and are 
thus unlikely to die while pregnant or post partum. This 
so-called healthy preg nant women eﬀ ect—a selection 
eﬀ ect whereby healthier women are the ones who become 
pregnant—has been described in other settings (where it 
is mainly due to the younger age of pregnant women 
relative to non-pregnant women), but is more strongly 
apparent when HIV is the main cause of death in adults.35
Provision of services to prevent mother-to-child trans-
mission of HIV probably did not confer health advantages 
to the pregnant women in this study. Most of the data 
(roughly 64%) relating to the mortality exposure of 
pregnant women were gathered before such services 
were widely available at the study sites. The drugs given 
in the early programmes to prevent mother-to-child 
transmission were one-oﬀ  doses close to the time of 
delivery (too late to aﬀ ect survival for most of the at-risk 
Figure 1: Mortality rates in HIV-infected and HIV-uninfected women, by 
pregnancy status and availability of ART
Pooled Analysing Longitudinal Population-based HIV/AIDS data on Africa 
(ALPHA) network data, 1990–2012. Bars are 95% CIs. ART=antiretroviral 
therapy. PPP=pregnant or post partum.
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period). The aim was to decrease the probability of 
transmission to the neonate rather than to improve the 
mother’s survival chances. WHO’s 2010 guidelines36 
include recommendations for ART aimed at improve-
ment of survival of mothers, but these guidelines had not 
yet been implemented at any of the study sites during the 
study, and by 2011–12, pregnant or post-partum women 
had not beneﬁ ted signiﬁ cantly from ART availability, 
unlike their non-pregnant counterparts. 
The PAF of 44·6% corres ponded to an overall mean 
prevalence of HIV infection of 17·2% in the ALPHA 
surveillance popu lations; the crude rate ratio in the pooled 
dataset was 8·2. On the basis of the standard relations 
between PAF, prevalence, and rate ratio, we expected a 
PAF for HIV of around 24% in pregnancy-related 
mortality for sub-Saharan Africa, whereas the Joint UN 
Programme on HIV/AIDS (UNAIDS) estimate that the 
2010 prevalence of HIV infection in pregnant women is 
4·4% (unpublished).37 The results of a system atic review13 
showed that an estimated 25% of pregnancy-related 
deaths were attributable to HIV in sub-Saharan Africa. 
Globally, the equivalent estimate for the pro portion of 
pregnancy-related deaths attributable to HIV is roughly 
8%, which is based on the (unpublished) UNAIDS global 
estimate of 1·2% prevalence of HIV infec tion in pregnant 
women.37 We would expect the proportion of maternal 
mortality attributable to HIV to be less than this estimate 
if some of the AIDS deaths in pregnant or post-partum 
women are classiﬁ ed as incidental to pregnancy.
Modelled estimates for the proportion of maternal 
mortality attributable to HIV in sub-Saharan Africa range 
from 10% to 32%.4,38 However, conﬁ dential inquiries in 
South Africa suggest that roughly 70% of pregnant or 
post-partum women who die in hospital might be HIV 
infected,12,39 and estimates based on these data suggest a 
PAF for HIV of about 58%. In the pooled ALPHA dataset, 
51% of the pregnant or post-partum women who died 
were infected with HIV. The standard relations between 
PAF, prevalence, and rate ratio led us to expect a PAF for 
HIV of 56% in South African institutional pregnancy-
related deaths—very close to the noted ﬁ gure. 
The overall ratio of pregnancy-related deaths to preg-
nancies for all sites was 270 per 100 000 pregnancies— 
1015 per 100 000 in HIV-infected women and 119 per 
100 000 in HIV-uninfected women. In view of the fact 
that women in sub-Saharan Africa have very low access 
to high-quality obstetric care, these ratios are low and 
generally fall below the modelled maternal mortality 
estimates for sub-Saharan Africa in 1990–2010 
published by WHO (850 per 100 000 in HIV-infected 
women and 500 per 100 000 in HIV-uninfected women)4 
and the Institute for Health Metrics and Evaluation 
(490 per 100 000 in HIV-infected women and 170 per 
100 000 in HIV-uninfected women).5 However, the 
ratios in the ALPHA dataset (1015 per 100 000 for HIV-
infected women, 270 per 100 000 for HIV-uninfected 
women) were higher than institutional ratios for 
pregnancy-related deaths reported in South Africa 
(430 per 100 000 for HIV-infected women, 75 per 100 000 
for HIV-uninfected women).12 HIV ascertainment was 
not related to the ascertainment of pregnancy, so the 
probable under estimation of pregnancy-related deaths 
should not aﬀ ect the rate-ratio comparisons of 
pregnancy-related mortality in HIV-infected and HIV-
uninfected women.
Our study has several limitations. Even after pooling of 
the data from all six studies we identiﬁ ed only 
235 pregnancy-related deaths. Compared with studies 
designed to track maternal deaths by frequent checks on 
pregnancy status and close surveillance of pregnant 
women, the ALPHA community studies, which were 
designed for HIV surveillance, did not detect all pregnancy-
related deaths. Several factors might contribute to this 
failure to detect pregnancy-related deaths. Pregnancies 
might not be reported because women are embarrassed or 
because of proxy reporting by other household members. 
Furthermore, studies that undertake demographic surveil-
lance with intervals longer than 6 months would not 
intersect with all the times during which women would 
recognise that they were pregnant. 
Verbal autopsy seems a more reliable way to identify 
pregnancy-related deaths than is the demographic sur-
veillance system, and thus, because 1868 (27·6%) of all 
deaths in the pooled dataset did not have an associated 
verbal autopsy, we might have missed some pregnancy-
related deaths. 184 of 4892 (3·8%) deaths for which verbal 
Panel: Research in context
Systematic review
To review the evidence on the proportion of maternal deaths attributable to HIV in Africa 
we relied on three sources. First, a systematic review7 of the causes of maternal deaths 
published in 2006 reported the proportion of maternal deaths in Africa attributable to HIV, 
but this review was based on only eight studies and methods to assign a death to HIV were 
not reported. Second, we searched PubMed, Embase, Popline, and African Index Medicus 
for studies comparing mortality during pregnancy and the post-partum period between 
HIV-infected and HIV-uninfected women.13 We identiﬁ ed 23 studies, which were published 
between 1991 and 2009. 17 were from sub-Saharan Africa, of which only two were 
population based.32,33 Third, we examined the modelled estimates published by the 
Institute for Health Metrics and Evaluation5 for 2011 and the Maternal Mortality 
Estimation Inter-agency Group4 for 2010. These models vary in their underlying 
assumptions, including those about whether deaths in HIV-infected pregnant or 
post-partum women should be classiﬁ ed as maternal, and results vary greatly.
Interpretation
Our study is, to our knowledge, the ﬁ rst to estimate the proportion of pregnancy-related 
or post-partum-related deaths attributable to HIV on the basis of empirical data from six 
community-based studies in eastern and southern Africa with HIV serological surveillance 
and verbal autopsies. HIV-infected pregnant or post-partum women have roughly eight 
times higher mortality than do their HIV-uninfected counterparts, and the excess mortality 
attributable to HIV in pregnant or post-partum women varies substantially depending on 
prevalence. Our ﬁ ndings emphasise the need to extend the focus of safe motherhood 
programmes beyond direct obstetric causes of death and call for a more rigorous 
assessment of HIV as a cause of pregnancy-related deaths. 
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autopsies were done seemed to be pregnancy related, 
whereas only 24 of 1868 (1·3%) of those for which verbal 
autopsies were not done were identiﬁ ed as pregnancy 
related from the demographic surveillance system. On 
the basis of typical capture–recapture assumptions (ie, 
that the likelihood of a death being related to pregnancy is 
independent of acquisition of verbal-autopsy data), we 
estimate that universal coverage of verbal autopsies could 
have identiﬁ ed about 50 more pregnancy-related deaths, 
implying an overall under estimate of roughly 18% in 
the number of pregnancy-related deaths. However, this 
underestimate is unlikely to be related to HIV status, 
because we noted no signs of a relation between verbal 
autopsy and HIV ascertainment. 
Interstudy variation in the frequency of serological 
surveillance and prevalence of HIV infection meant that 
varying numbers of person-years after the last HIV-
negative test were censored by transferring individuals 
to the unknown HIV status category, ranging from 
1·5 years in uMkhanyukude to 5 years in Karonga, 
Kisesa, Masaka, and Rakai. The sensitivity analysis in 
the appendix shows that the eﬀ ect of our assumptions 
on the mortality rate ratios of pregnant or post-partum 
women was insigniﬁ cant. Similarly, the sensitivity 
analysis for the length of time spent infected with HIV 
by women who were identiﬁ ed as being infected only by 
verbal autopsy shows that estimates of mortality rate 
ratios were not aﬀ ected.
HIV status was more likely to be missing for women 
who died than for women in general, and in all studies, 
death rates in women with unknown HIV status were 
higher than those in women whose HIV status was known, 
suggesting that the prevalence of HIV infection in women 
whose HIV status was known under estimated overall 
prevalence. A crude application of the mortality-rate-
adjustment method for estimation of recorded prevalence 
of HIV infection allowing for under-reporting (which was 
developed in the Africa Centre40) suggested that the overall 
mean prevalence of HIV infection might have been 
underestimated by as much as 30% in the pooled dataset—
partly a result of the high prevalence in data from the 
Africa Centre, which also has the highest proportion of 
women with unknown HIV statuses. Higher prevalence of 
HIV infection in each contributing study would raise the 
PAF of deaths due to HIV in all women, but especially in 
those who were not pregnant or post partum.
Our results show that, in populations with a high 
prevalence of HIV infection, a very high proportion of 
deaths during pregnancy or the post-partum period 
were attributable to HIV. HIV and reproductive health 
services need to be integrated with safe motherhood 
programmes, and the focus of safe motherhood 
campaigns should be extended beyond direct obstetric 
causes of death. Many national HIV control pro-
grammes are widening access to ART. In 2013, South 
Africa will enable all HIV-infected pregnant women to 
receive treatment from early pregnancy throughout the 
duration of breastfeeding, and other countries, such as 
Malawi, are already providing all HIV-infected pregnant 
women with lifelong ART. Such wider eligibility criteria 
should cause HIV-related deaths in women of 
childbearing age to decline rapidly if safe motherhood 
programmes ensure that pregnant women discovered 
to be infected with HIV are actively encouraged to take 
up ART, over and above the routine advice that is 
provided about prevention of HIV transmission to the 
unborn child.
Contributors
BZ, PB, TB, and CR conceived the study. BZ, CC, and CR wrote and 
revised the Article. BZ organised data collaboration, interpreted 
statistical analyses, and wrote and revised the Article. CC collated and 
checked multiple-site data, ran and interpreted statistical analyses, and 
wrote and revised the Article. MM collated and checked 
multiple-site data, wrote statistical programmes, and ran and interpreted 
statistical analyses. RI, JN-M, TL, AC, LR, and KH were responsible for 
data collection and preparation at the various study sites and commented 
on the Article. M-LN interpreted ﬁ ndings from the Africa Centre and 
helped with text revisions. JT organised data collaboration, interpreted 
statistical analyses, and helped with text revisions. PB commented on 
statistical analyses and text. TB commented on statistical analyses and 
helped with text revisions. CR interpreted statistical analyses.
Conﬂ icts of interest
All authors received travel grants through the ALPHA Network to attend 
short workshops hosted at the study sites, at which they prepared and 
analysed the data and discussed the provisional results. We declare that 
we have no conﬂ icts of interest. 
Acknowledgments
The ALPHA network is funded by the Wellcome Trust. The six study 
sites contributing data (the ALPHA network members) are funded by 
the Wellcome Trust, Global Fund to Fight AIDS, Tuberculosis and 
Malaria, US National Institutes of Health, and UK Medical Research 
Council. Workshops at which the data were collated, cleaned, and 
analysed were funded by the Health Metrics Network (WHO). CC was 
supported by an Economic and Social Research Council PhD fellowship.
References 
 1 UNAIDS. Countdown to zero: Global plan towards the elimination 
of new HIV infections among children by 2015 and keeping their 
mothers alive. Geneva: Joint United Nations Programme on HIV 
and AIDS, 2011.
 2 Porter K, Zaba B. The empirical evidence for the impact of HIV on 
adult mortality in the developing world: data from serological 
studies. AIDS 2004; 18 (suppl 2): S9–17.
 3 Zaba B, Marston M, Crampin AC, et al. Age-speciﬁ c mortality 
patterns in HIV-infected individuals: a comparative analysis of 
African community study data. AIDS 2007; 21: S87–96. 
 4 WHO. Trends in maternal mortality: 1990–2012. Geneva: World 
Health Organization, 2012.
5 Lozano R, Wang H, Foreman KJ, et al. Progress towards 
Millennium Development Goals 4 and 5 on maternal and child 
mortality: an updated systematic analysis. Lancet 2011; 
378: 1139–65.
 6 Bicego G, Boerma JT, Ronsmans C. The eﬀ ect of AIDS on maternal 
mortality in Malawi and Zimbabwe. AIDS 2002; 16: 1078–81.
 7 Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. WHO 
analysis of causes of maternal death: a systematic review. Lancet 
2006; 367: 1066–74.
 8 Ahmed Y, Mwaba P, Chintu C, Grange JM, Ustianowski A, 
Zumla A. A study of maternal mortality at the University Teaching 
Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major 
non-obstetric cause of maternal death. Int J Tuberc Lung Dis 1999; 
3: 675–80.
 9 Black V, Brooke S, Chersich MF. Eﬀ ect of human 
immunodeﬁ ciency virus treatment on maternal mortality at a 
tertiary center in South Africa: a 5-year audit. Obstet Gynecol 2009; 
114: 292–99.
Articles
www.thelancet.com   Vol 381   May 18, 2013 1771
 10 Kongnyuy EJ, Mlava G, van den Broek N. Facility-based maternal 
death review in three districts in the central region of Malawi: an 
analysis of causes and characteristics of maternal deaths. 
Womens Health Issues 2009; 19: 14–20.
 11 Van Dillen J, Meguid T, van Roosmalen J. Maternal mortality audit 
in a hospital in northern Namibia: the impact of HIV/AIDS. 
Acta Obstet Gynecol Scand 2006; 85: 499–500.
 12 Chweneyagae D, Delis-Jarrosay N, Farina Z, et al. The impact of 
HIV infection on maternal deaths in South Africa. S Afr J OG 2012; 
18: 70–76.
 13 Calvert C, Ronsmans C. The contribution of HIV to pregnancy-related 
mortality: a systematic review and meta-analysis. AIDS 2013; 
published online Feb 25. DOI:10.1097/QAD.0b013e32835fd940.
 14 Maher D, Biraro S, Hosegood V, et al. Translating global health 
research aims into action: the example of the ALPHA network. 
Trop Med Int Health 2010; 15: 321–28.
 15 Jahn A, Branson K, Crampin AC, et al. Evaluation of a 
village-informant driven demographic surveillance system in 
Karonga, northern Malawi. Demographic Res 2007; 16: 219–48.
 16 Welz T, Herbst K. Anonymous HIV testing with 
participant-controlled access to results using handheld computers: 
a new model of HIV testing used in a household survey in rural 
South Africa. Sex Transm Dis 2008; 35: 372–76. 
 17 Todd J, Glynn JR, Marston M, et al. Time from HIV seroconversion 
to death: a collaborative analysis of eight studies in six low and 
middle-income countries before highly active antiretroviral therapy. 
AIDS 2007; 21: S55–63. 
 18 Boerma JT, Urassa M, Senkoro K, Klokke A, Ngweshemi JZ. Spread 
of HIV infection in a rural area of Tanzania. AIDS 1999; 
13: 1233–40.
 19 Gregson S, Mason PR, Garnett GP, et al. A rural HIV epidemic 
in Zimbabwe? Findings from a population-based survey. 
Int J STD AIDS 2001; 12: 189–96.
 20 Kengeya-Kayondo J, Kamali A, Nunn A, Ruberantwari A, 
Wagner H, Mulder D. Incidence of HIV-1 infection in Adults and 
Socio-demographic characteristics of seroconverters in a rural 
population in Uganda: 1990–1994. Int J Epidemiol 1996; 
25: 1077–82.
 21 Crampin AC, Glynn JR, Ngwira BM, et al. Trends and measurement 
of HIV prevalence in northern Malawi. AIDS 2003; 17: 1817–25.
 22 Welz T, Hosegood V, Jaﬀ ar S, Bätzing-Feigenbaum J, Herbst K, 
Newell M-L. Continued very high prevalence of HIV infection in 
rural KwaZulu-Natal, South Africa: a population-based longitudinal 
study. AIDS 2007; 21: 1467–72. 
 23 Kamali A, Carpenter LM, Whitworth JAG, Pool R, Ruberantwari A, 
Ojwiya A. Seven-year trends in HIV-1 infection rates, and changes 
in sexual behaviour, among adults in rural Uganda. AIDS 2000; 
14: 427–34.
 24 Konde-Lule JK, Wawer MJ, Sewankambo NK, et al. Adolescents, 
sexual behavior and HIV-1 in rural Rakai district, Uganda. AIDS 
1997; 11: 791–99.
 25 Mwaluko G, Urassa M, Isingo R, Zaba B, Boerma JT. Trends in HIV 
and sexual behaviour in a longitudinal study in a rural population 
in Tanzania, 1994–2000. AIDS 2003; 17: 2645–51.
 26 Lopman B, Nyamukapa C, Mushati P, et al. HIV incidence in 
3 years of follow-up of a Zimbabwe cohort—1998–2000 to 2001–03: 
contributions of proximate and underlying determinants to 
transmission. Int J Epidemiol 2008; 37: 88–105.
 27 Soleman N, Chandramohan D, Shibuya K. Verbal autopsy: current 
practices and challenges. Bull World Health Organ 2006; 84: 239–45.
 28 Setel PW, Rao C, Hemed Y, et al. Core verbal autopsy procedures 
with comparative validation results from two Countries. PLoS Med 
2006; 3: e268.
 29 Baiden F, Bawah A, Biai S, et al. Setting international standards for 
verbal autopsy. Bull World Health Organ 2007; 85: 570–71.
 30 WHO. International statistical classiﬁ cation of diseases and related 
health problems, tenth revision. Geneva: World Health 
Organization, 2010.
 31 Kirkwood BR, Sterna JAC. Medical statistics. Oxford: Blackwell 
Science, 2003.
32 Le Coeur S, Khlat M, Halembokaka G, et al. HIV and the 
magnitude of pregnancy-related mortality in Pointe Noire, Congo. 
AIDS 2005; 19: 69–75.
33 Sewankambo NK, Gray RH, Ahmad S, et al. Mortality associated 
with HIV infection in rural Rakai District, Uganda. AIDS 2000; 
14: 2391–2400.
 34 Lewis JJ, Ronsmans C, Ezeh A, Gregson S. The population impact 
of HIV on fertility in sub-Saharan Africa. AIDS 2004; 18: S35–43.
 35 Ronsmans C, Khlat M, Kodio B, Ba M, De Bernis L, Etard J. 
Evidence for a ‘healthy pregnant woman eﬀ ect’ in Niakhar, Senegal? 
Int J Epidemiol 2001; 30: 467–73.
 36 WHO. Antiretroviral drugs for treating pregnant women and 
preventing HIV infections in infants: recommendations for a public 
health approach, 2010 version. Geneva: World Health Organization, 
2010.
 37 UNAIDS. Unpublished estimates from the “Global Report: 
UNAIDS Report on the global AIDS epidemic”. Geneva: Joint 
United Nations Programme on HIV and AIDS, 2012.
 38 Rosen JE, de Zoysa I, Dehne K, Mangiaterra V, Abdool-Karim Q. 
Understanding methods for estimating HIV-associated maternal 
mortality. J Pregnancy 2012; 2012: 958262.
 39 National Committee on Conﬁ dential Enquiries into Maternal Deaths. 
Saving mothers 2005–2007: fourth report on conﬁ dential enquiries 
into maternal deaths in South Africa. http://www.doh.gov.za/docs/
reports/2007/savingmothers.pdf (accessed May 1, 2013).
40 Nyirenda M, Zaba B, Bärnighausen T, Hosegood V, Newell M-L. 
Adjusting HIV prevalence for survey non-response using mortality 
rates: an application of the method using surveillance data from 
rural South Africa. PLoS One 2010; 5: e12370.
© 2013. World Health Organization. Published by Elsevier Ltd/Inc/BV. 
All rights reserved.
